TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19913143

Group type: EXPERIMENTAL
Intervention: Continuous LNG 90 mcg/EE 20 mcg
Number of subjects: 641

Group type: COMPARATOR
Intervention: Cyclic LNG 100 mcg/EE 20 mcg
Number of subjects: 641
Study: 17149671

Group type: EXPERIMENTAL
Intervention: Provider-delivered, individualized, stage-based interventions; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audio-computerized-assisted, self-interviewing systems; details on dosage and duration not available.
Number of subjects: 0
Study: 15221293

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 53
Study: 12670085

Group type: EXPERIMENTAL
Intervention: SRP + MPTS (scaling and root-planing followed by one dose per pocket of minocycline microspheres, 1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRP + MPTS
Number of subjects: 0

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: MPTS alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 9825187

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 1775

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1775
Study: 8009754

Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g n‐3 fatty acids per day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Olive oil (4 1‐g capsules per day)
Number of subjects: 533

Group type: COMPARATOR
Intervention: No oil supplementation
Number of subjects: 533
Study: 2691476

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate (3.1 g every 4 h)
Number of subjects: 112

Group type: COMPARATOR
Intervention: gentamicin plus clindamycin (900 mg every 8 h)
Number of subjects: 112
Study: 1091001

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (5 gm three times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride
Number of subjects: 60
Study: 30455329

Group type: EXPERIMENTAL
Intervention: Incessant increase OGTT glucose response curve
Number of subjects: 662

Group type: COMPARATOR
Intervention: Monophasic OGTT glucose response curve
Number of subjects: 662

Group type: COMPARATOR
Intervention: Biphasic OGTT glucose response curve
Number of subjects: 662
Study: 28039643

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 26
Study: 25504487

Group type: EXPERIMENTAL
Intervention: Education and daily exercise (4 spinal movements for daily practice)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 708
Study: 23779114

Group type: EXPERIMENTAL
Intervention: High diet (45% of energy from fat, >25% saturated fat, 35%-40% from carbohydrates with a mean glycemic index >70, and 15%-20% from protein)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low diet (25% of energy from fat, <7% saturated fat, 55%-60% from carbohydrates with a mean glycemic index <55, and 15%-20% from protein)
Number of subjects: 47
Study: 22239052

Group type: EXPERIMENTAL
Intervention: Ambroxol (B group)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Eucalyptol-limonene-pinene enteric soft capsule (C group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (A group)
Number of subjects: 97
Study: 19845513

Group type: EXPERIMENTAL
Intervention: Fixed Atenolol Amlodipine Combination (FAAC) monotherapy
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Fixed Atenolol Amlodipine Combination (FAAC) in combination therapy
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Fixed Atenolol Amlodipine Combination (FAAC)
Number of subjects: 570
Study: 16974191

Group type: EXPERIMENTAL
Intervention: DHEA (200 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15153724

Group type: EXPERIMENTAL
Intervention: 10 mg of mitoxantrone (6 weekly and 20 fortnightly instillations)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 20 mg of mitoxantrone (3 fortnightly and 10 monthly instillations)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 100 MU of IFNalpha‐2b (8 weekly, 8 fortnightly and 6 monthly instillations)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 208
Study: 11420318

Group type: EXPERIMENTAL
Intervention: Early sodium supplementation (4 mmol/kg/day starting from 24 hours after birth)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed sodium supplementation (4 mmol/kg/day starting when a weight loss of 6% of birth weight was achieved)
Number of subjects: 0
Study: 9652560

Group type: EXPERIMENTAL
Intervention: rhIGF‐I 40 microg/kg daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rhIGF‐I 20 microg/kg daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 8437014

Group type: EXPERIMENTAL
Intervention: Capgras delusion group
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (paranoid schizophrenics)
Number of subjects: 6
Study: 3317057

Group type: EXPERIMENTAL
Intervention: 5-ASA at a dosage of 4.8 g per day
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5-ASA at a dosage of 1.6 g per day
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 29797519

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Prior dose adjustment groups
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Randomised every 8 weeks
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Randomised every 12 weeks
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study: 27894316

Group type: EXPERIMENTAL
Intervention: Diet/physical activity intervention
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Dietary patterns (African/Caribbean and Processed)
Number of subjects: 1023
Study: 24257725

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 181
Study: 22521071

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 629

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 629
Study: 20537570

Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 87
Study: 18172059

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4728

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 4728
Study: 15844435

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (low energy laser to LU7, LI4, GB14, and GB20 bilaterally, 1.3J intensity, 10 sessions, 3 per week)
Number of subjects: 50
Study: 12695240

Group type: EXPERIMENTAL
Intervention: Corneas stored in organ culture for 5-12 days (group 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Corneas stored in organ culture for 21-24 days (group 2)
Number of subjects: 25
Study: 10475721

Group type: EXPERIMENTAL
Intervention: Olanzapine (3 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9084525

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg + 10 ml 2% lidocaine before general anesthesia (group II)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg + 3 ml 2% lidocaine before wound closure (group III)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-steroid analgesics (diclofenac sodium 50 mg, iv, q4h) (group I)
Number of subjects: 84
Study: 2017271

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine therapy (2 g i.v. 3 times weekly for 6 months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine therapy (1 g i.v. for 10 months after initial treatment)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (2 g i.v. 3 times weekly for 6 months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine therapy
Number of subjects: 14
Study: 6218109

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of mezlocillin (1 g every eight hours)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous administration of mezlocillin (2 g every eight hours)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both routes of administration (i.m. and i.v.)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of mezlocillin
Number of subjects: 50
Study: 31884075

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 80

Group type: COMPARATOR
Intervention: Turkish music
Number of subjects: 80

Group type: COMPARATOR
Intervention: Soft rock music
Number of subjects: 80

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 80
Study: 31584538

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0
Study: 27682227

Group type: EXPERIMENTAL
Intervention: 1st group (EDSS 0, 1)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 2nd group (EDSS 1.5, 2)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 3rd group (EDSS 2.5, 3)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 4th group (EDSS ≥3.5)
Number of subjects: 959
Study: 26137956

Group type: EXPERIMENTAL
Intervention: AZD3241 600 mg orally twice a day for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24858149

Group type: EXPERIMENTAL
Intervention: Labetalol (0.25 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl (2μgm/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (10ml of 0.9% saline)
Number of subjects: 90
Study: 22292526

Group type: EXPERIMENTAL
Intervention: i.v. alteplase (rt-PA) at a dosage of 0.9 mg/kg of body weight
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard treatment according to national guidelines
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: i.v. alteplase (rt-PA)
Number of subjects: 600
Study: 19274758

Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 655

Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 655
Study: 17584058

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha monoclonal antibodies
Number of subjects: 0
Study: 15132753

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10) trained their respiratory muscles via 20, 45 min sessions of hyperpnea
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo group (n = 4) underwent 'sham' training (20, 5 min sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 6) did no training
Number of subjects: 20
Study: 15020186

Group type: EXPERIMENTAL
Intervention: SMS reminders for vaccination doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control 2001 (no SMS reminders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control 2000 (no SMS reminders)
Number of subjects: 0
Study: 10479167

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-alpha
Number of subjects: 180

Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination therapy with low-dose IFN-alpha
Number of subjects: 180
Study: 8743976

Group type: EXPERIMENTAL
Intervention: TBARS concentration in subretinal fluid (SF)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: TBARS concentration in SF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Correlation between TBARS and protein contents in SF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Evolution time of retinal detachment
Number of subjects: 38
Study: 1820675

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg intramuscular)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 0
Study: 6293073

Group type: EXPERIMENTAL
Intervention: Hormonal therapy with tamoxifen and drostanolone propionate (n = 34)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Chemotherapy with the CMF protocol (n = 30)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Combination of hormonal therapy and chemotherapy (n = 34)
Number of subjects: 98
Study: 31964377

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31587960

Group type: EXPERIMENTAL
Intervention: Bruder Compress twice a day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bruder Compress once a day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Warm washcloth used for ten minutes twice a day without reheating
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bruder Compress (both groups)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bruder Compress twice daily vs once daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bruder Compress
Number of subjects: 51
Study: 29748349

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 2002
Study: 26524618

Group type: EXPERIMENTAL
Intervention: Brief couples intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 215
Study: 24345602

Group type: EXPERIMENTAL
Intervention: Multi-level intervention targeting nutrition and physical activity environment, social environment, individual knowledge, attitudes and skills
Number of subjects: 782

Group type: COMPARATOR
Intervention: Materials only condition (control)
Number of subjects: 782
Study: 21343342

Group type: EXPERIMENTAL
Intervention: A0001 (α-tocopherylquinone) at doses of 0.25 g and 0.5 g under fasted state; 0.5 g to 6 g with high-fat meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: A0001 (α-tocopherylquinone) administered in divided doses (0.735 g, 3 times per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19903574

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg once daily
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 17378175

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody A33 in Phase I trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapies in Phase II trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: New therapy using newly developed material in Phase III trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertension agents in Phase III trial
Number of subjects: 0
Study: 16253589

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent implantation
Number of subjects: 45
Study: 11867968

Group type: EXPERIMENTAL
Intervention: minocycline 100/50 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: lymecycline 300 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: minocycline 50 mg
Number of subjects: 86
Study: 9865617

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZM) 500 mg/day for 2 weeks
Number of subjects: 9
Study: 7830728

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg twice daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30531676

Group type: EXPERIMENTAL
Intervention: Group DS2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Norepinephrine, IL-6, TNF-a
Number of subjects: 100
Study: 27537209

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) plus stretching (n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Stretching only (control group) (n = 65)
Number of subjects: 130
Study: 24523666

Group type: EXPERIMENTAL
Intervention: Lower intensity renal replacement therapy (RRT)
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Higher intensity renal replacement therapy (RRT)
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Lower intensity RRT among survivors to day 90
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Higher intensity RRT among survivors to day 90
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Lower intensity RRT
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Higher intensity RRT
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 1464
Study: 23013489

Group type: EXPERIMENTAL
Intervention: Immediate exercise program (6 months)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Delayed exercise program (6 months after usual care)
Number of subjects: 124
Study: 19723080

Group type: EXPERIMENTAL
Intervention: Grape Juice (5.5 mL/kg daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo Juice (isocaloric for 8 weeks)
Number of subjects: 40
Study: 16951956

Group type: EXPERIMENTAL
Intervention: Radiosynoviorthesis (RSO) with intra‐articular radionuclide plus glucocorticoid (GC) injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo plus glucocorticoid (GC) injection
Number of subjects: 44
Study: 15316468

Group type: EXPERIMENTAL
Intervention: Mandibular sagittal split osteotomy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Herbst appliance
Number of subjects: 69
Study: 11559545

Group type: EXPERIMENTAL
Intervention: ICI 182,780 50 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ICI 182,780 125 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ICI 182,780 250 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9786257

Group type: EXPERIMENTAL
Intervention: Conventional long-term anticoagulation (LTA) therapy: initial intravenous standard heparin followed by warfarin on days 3 to 5, continued for 3 months.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation therapy: same heparin therapy followed by warfarin on days 2 to 3, continued for 6 weeks.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Short-term anticoagulation therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional long-term anticoagulation (LTA) therapy
Number of subjects: 105
Study: 8152348

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) 20 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: n-6 PUFA 20 g
Number of subjects: 40
Study: 2463524

Group type: EXPERIMENTAL
Intervention: Pacemaker implant (VVI or DDD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 35
Study: 28513326

Group type: EXPERIMENTAL
Intervention: BFR+NMES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NMES alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BFR alone
Number of subjects: 20
Study: 28836493

Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation package (patient-held information workbook, goal-setting diary, six additional therapy sessions)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Usual care plus an enhanced rehabilitation package
Number of subjects: 62
Study: 26633830

Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Happiness condition
Number of subjects: 61
Study: 24165282

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen treatment for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment for three months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen treatment
Number of subjects: 30
Study: 21373203

Group type: EXPERIMENTAL
Intervention: pulsed‐continuous arterial spin‐labelling (pCASL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: pCASL
Number of subjects: 16
Study: 18210310

Group type: EXPERIMENTAL
Intervention: Anesthetic cream (lidocaine/prilocaine) applied prior to galactography in Group B (27 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No anesthetic cream in Group A (19 patients)
Number of subjects: 46
Study: 16088358

Group type: EXPERIMENTAL
Intervention: Prolene
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: VyproII
Number of subjects: 140
Study: 12826434

Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulphate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison between magnesium and saline
Number of subjects: 52
Study: 10755054

Group type: EXPERIMENTAL
Intervention: Attenders
Number of subjects: 365

Group type: COMPARATOR
Intervention: Non-attenders
Number of subjects: 365
Study: 8660042

Group type: EXPERIMENTAL
Intervention: D-penicillamine treatment
Number of subjects: 29
Study: 1819153

Group type: COMPARATOR
Intervention: 40 mg frusemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination tablet (40 mg frusemide and 5 mg amiloride)
Number of subjects: 12
Study: 6345111

Group type: EXPERIMENTAL
Intervention: Liquid antacid (Maalox Therapeutic Concentration, 15 ml, 80 mEq, taken 7 times daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (taken 7 times daily)
Number of subjects: 32
Study: 30126028

Group type: EXPERIMENTAL
Intervention: High-dose peanut OIT (3000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose peanut OIT (300 mg)
Number of subjects: 0
Study: 29098683

Group type: EXPERIMENTAL
Intervention: Sufentanil (target‐controlled infusion, effect‐site concentration of 0.3 ng.ml‐1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 71
Study: 27402372

Group type: EXPERIMENTAL
Intervention: Early feeding (access to liquids and regular diet on postoperative days 1 and 2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (introduction of a liquid diet after return of bowel activity, typically days 3-5)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102